Organon & Co. (NYSE:OGN) is among the 7 Oversold Pharma Stocks to Buy Now. Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% Organon & Co. (NYSE:OGN) is among the most oversold pharma stocks. TheFly reported on February 12 that OGN announced its fourth-quarter and full-year 2025 financial results. According to the report, for the full year, the company’s revenue totaled $6.2 billion, which represents a 3% decline both on a reported basis and in constant currency. Diluted earning ...

Sanofi (NASDAQ:SNY) is among the 7 Oversold Pharma Stocks to Buy Now. Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA Sanofi (NASDAQ:SNY) is one of the most oversold stocks. TheFly reported that on February 20, SNY’s price target was lowered at Citi by EUR 5. On the other hand, earlier on February 12, BofA reduced its price target for SNY from EUR 102 to EUR 92 and downgraded the stock from Buy to Neutral. Following the announcement that Belén Garijo, the former CEO of Merck KGaA, wi ...

th PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a fireside chat beginning at 9:50 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives T ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

Market Overview - The Dow Jones Industrial Average closed down 821.91 points (-1.66%) at 48,804.06, with Dow Futures falling 857.00 points (-1.73%) to 48,817.00, driven by a sudden 15% blanket tariff announcement that reignited trade war fears and global economic uncertainty [1] - The Federal Reserve's hawkish commentary suggested a "coin flip" for future rate cuts, leading to a significant rotation from cyclical and growth sectors into defensive assets [1] Sector Performance Financial Sector - Financial stocks were the primary laggards amid rising recessionary fears, with American Express (AXP) dropping 7.48% to $320.12, JPMorgan Chase & Co. (JPM) falling 4.19% to $297.74, and Goldman Sachs (GS) decreasing by 3.44% [2] Technology Sector - The tech sector faced pressure due to AI-related disruption fears, with Salesforce (CRM) tumbling 5.10%, IBM (IBM) shedding 4.17%, and Microsoft (MSFT) declining by 2.61% [2] Defensive Sectors - Investors sought safety in consumer staples and healthcare, with Walmart (WMT) leading gainers at 2.76% to $126.43, followed by Procter & Gamble (PG) at 2.50%, and McDonald's (MCD) gaining 1.84% [3] - Apple (AAPL) bucked the tech trend with a 1.81% increase to $269.28, while healthcare giants Amgen (AMGN) and Johnson & Johnson (JNJ) advanced 1.57% and 1.32%, respectively [3]

New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-Nationa ...

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWS ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company concealed manufacturing deficiencies related to its CELLECTRA device, which is crucial for its DNA medicine platform, leading to significant delays in the Biologics License Application submission timeline [1][2][3]. Group 1: Allegations of Manufacturing Deficiencies - The lawsuit claims that Inovio represented its CELLECTRA devices as "validated and manufactured under Current Good Manufacturing Practices (cGMP)" while allegedly hiding manufacturing issues with the single-use disposable administration component [2][4]. - A specific manufacturing issue was identified during routine testing, which is said to have stemmed from a plastic molded part within the array component [4][7]. Group 2: Impact on Biologics License Application (BLA) - The complaint alleges that these manufacturing deficiencies caused a full-year delay in the BLA submission timeline, moving the projected submission from the second half of 2024 to mid-2025 [3][7]. - Retesting of the CELLECTRA device was required due to these issues, further extending the timelines for the BLA submission [7]. Group 3: Importance of Accurate Disclosure - The integrity of the CELLECTRA device is deemed critical to Inovio's commercial transition, making accurate disclosure of its manufacturing status essential for investors [4]. - The case raises significant questions regarding manufacturing disclosure obligations within the biotechnology sector, highlighting the importance of transparency for investor trust [5].

Core Viewpoint - The FDA supports mRNA vaccines but believes that U.S. taxpayers should not bear the financial burden of their development, as companies involved can fund their own research [2][8]. Group 1: FDA's Position on mRNA Vaccines - FDA Commissioner Marty Makary defended the agency's stance on mRNA vaccines, stating that the FDA has approved two mRNA vaccines for RSV [3]. - The FDA is reviewing a Moderna flu vaccine, indicating ongoing support for mRNA technology [1][2]. Group 2: Funding Decisions and Rationale - The U.S. Department of Health and Human Services (HHS) cut funding for mRNA vaccine research, with Makary explaining that companies like Moderna and Pfizer, which made over $50 billion, can afford their own research [5][8]. - The HHS's decision to defund mRNA vaccine development was influenced by a belief that the vaccines were not effectively protecting against respiratory infections, despite contrary scientific evidence [5][6]. Group 3: Future Research Directions - Makary emphasized the need for government funding to focus on underfunded areas such as rare diseases and bespoke conditions, rather than mRNA vaccine research [9].